Livedoid skin reaction to 2nd dose of mRNA Covid-19 vaccine

被引:4
作者
Girolami, Ilaria [1 ]
Eisendle, Klaus [2 ,3 ]
Kluge, Reinhard Walther [1 ]
Hanspeter, Esther [1 ]
Eccher, Albino [4 ]
Vizziello, Leonardo [2 ,3 ]
Zampieri, Pierfrancesco [3 ,5 ]
Mazzoleni, Guido [1 ]
机构
[1] Prov Hosp Bolzano SABES ASDAA, Dept Pathol, Bolzano, Italy
[2] Prov Hosp Bolzano SABES ASDAA, Dept Dermatol, Bolzano, Italy
[3] Lehrkrankenhaus Paracelsus Med Privatuniv, Via L Boehler 5, I-39100 Bolzano, Italy
[4] Univ & Hosp Trust Verona, Dept Pathol & Diagnost, Verona, Italy
[5] Hosp Merano SABES ASDAA, Dept Dermatol, Merano Meran, Italy
关键词
Covid-19; vaccine; drug eruption; skin; mRNA vaccine; VASCULITIS;
D O I
10.32074/1591-951X-746
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Skin often represents a target organ for adverse drug reactions and this also applies to the mRNA vaccines against Sars-CoV-2. Here we present a case of extensive livedoid reaction after 2nd dose of BNT162b-2 vaccine with massive blood skin extravasation and no systemic symptoms apart from anemization. The 30-year-old woman developed progressively enlarging livedoid lesions on limbs and abdomen. Histology showed a near-normal epidermis and a very mild interstitial mixed inflammatory infiltrate with extensive blood extravasation in mid- and deep dermis. Diagnosis was adverse reaction to vaccine with skin capillary hyperpermeability and anaemization with lower than diagnostic features of cutaneous small vessel vasculitis. To date, no cases of a livedoid skin reaction associated to Covid-19 vaccine have been reported, and this case illustrates that massive livedoid reaction can be another kind of skin reaction to mRNA Covid-19 vaccine.
引用
收藏
页码:322 / 325
页数:4
相关论文
共 50 条
  • [31] Thyroiditis After COVID-19 mRNA Vaccine: A Case Series
    Pandya, Manthan
    Thota, Geethika
    Wang, Xiangbing
    Luo, Hongxiu
    AACE CLINICAL CASE REPORTS, 2022, 8 (03): : 116 - 118
  • [32] Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report
    Mohammed, Lina M.
    Dhillon, Vikramjeet
    Bong, Juyong Peter
    Patri, Jyothi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
  • [33] mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
    Chavda, Vivek P.
    Jogi, Gargi
    Dave, Srusti
    Patel, Bhoomika M.
    Vineela Nalla, Lakshmi
    Koradia, Krishna
    VACCINES, 2023, 11 (03)
  • [34] Severe rhabdomyolysis secondary to COVID-19 mRNA vaccine in a teenager
    Pucchio, Aidan
    Akiva, Maya Heled
    Evangeliou, Helena
    Papenburg, Jesse
    Salvadori, Marina, I
    PEDIATRIC NEPHROLOGY, 2023, 38 (06) : 1979 - 1983
  • [35] The COVID-19 pfizer BioNTech mRNA vaccine and the frequency of seizures
    Doron, Alon
    Eviatar-Ribak, Tamar
    Vituri, Aya
    Shahar, Shimon
    Fahoum, Firas
    Goldstein, Lilach
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2023, 233
  • [36] Severe rhabdomyolysis secondary to COVID-19 mRNA vaccine in a teenager
    Aidan Pucchio
    Maya Heled Akiva
    Helena Evangeliou
    Jesse Papenburg
    Marina I. Salvadori
    Pediatric Nephrology, 2023, 38 : 1979 - 1983
  • [37] Delayed Skin Reactions to COVID-19 mRNA-1273 Vaccine: Case Report and Literature Review
    Wang, Ruei-Lin
    Chiang, Wen-Fang
    Chiu, Chih-Chiun
    Wu, Kuo-An
    Lin, Chia-Yi
    Kao, Yung-Hsi
    Chuu, Chih-Pin
    Chan, Jenq-Shyong
    Hsiao, Po-Jen
    VACCINES, 2022, 10 (09)
  • [38] Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine
    Charmetant, Xavier
    Espi, Maxime
    Barba, Thomas
    Ovize, Anne
    Morelon, Emmanuel
    Mathieu, Cyrille
    Thaunat, Olivier
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (05) : 1442 - 1450
  • [39] Unilateral Acute Idiopathic Blind Spot Enlargement following Second Dose of Covid-19 mRNA Vaccine
    Shen, Carl
    Tennant, Matthew
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (06) : 1219 - 1221
  • [40] Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine: Correspondence
    Pan, Wei
    Yu, Diao
    Shi, Na
    Bao, Zheng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)